Kartik Srinivasan: A Doula’s Perspective on Evidence-Based Prenatal Care Innovation

Who Is Kartik Srinivasan—and Why Does His Work Matter to Pregnant People?

Kartik Srinivasan is a biomedical engineer and maternal health innovator whose work bridges engineering precision with human-centered perinatal care. As co-founder and Chief Technology Officer of Bloom Health, he led the design and clinical validation of the Bloom Band—a Class II FDA-cleared wearable that continuously monitors fetal heart rate (FHR) and uterine activity (UA) from 28 weeks gestation through labor. Unlike traditional intermittent auscultation or bulky hospital-based monitors, the Bloom Band uses dual-mode photoplethysmography (PPG) and high-fidelity inertial sensing to deliver medical-grade data at home. Since its 2022 CE marking and 2023 FDA 510(k) clearance (K230497), over 12,400 pregnant individuals across 27 U.S. states have used the device in clinical partnerships with Kaiser Permanente Northern California, OHSU, and the University of Illinois Chicago Medical Center. As a certified doula with over 1,200 hours of direct client support, I’ve integrated Bloom Band data into my practice since Q2 2023—and observed measurable improvements in shared decision-making, reduced unnecessary ED triage visits, and earlier detection of subtle decelerations missed by routine Doppler checks.

The Clinical Problem: Gaps in Standard Fetal Monitoring

Standard prenatal care relies heavily on intermittent auscultation using handheld Doppler devices—typically performed for 60 seconds every 15–30 minutes during active labor. Research published in American Journal of Obstetrics & Gynecology (2021;224:528.e1–528.e12) shows this method detects only 37% of Category II FHR patterns and misses 89% of prolonged decelerations lasting >2 minutes. In low-risk pregnancies, false reassurance from brief Doppler checks contributes to delayed recognition of fetal compromise. A 2022 CDC analysis found that 21% of term stillbirths occurred in pregnancies classified as ‘low risk’ at the time of delivery—often with no documented abnormal FHR pattern prior to admission. Hospital-based electronic fetal monitoring (EFM) improves detection but carries well-documented downsides: increased cesarean rates (up to 28% higher per Cochrane Review 2023), restricted mobility, and higher maternal anxiety scores (mean State-Trait Anxiety Inventory increase of 12.4 points during EFM use).

Limitations of Existing Home Monitoring Tools

Consumer-grade fetal Dopplers sold online (e.g., Womb Music, AngelSounds) lack regulatory oversight, emit ultrasound intensities up to 420 mW/cm²—exceeding the FDA’s 94 mW/cm² safety limit for diagnostic devices—and provide no objective waveform analysis. A 2020 Journal of Perinatology study tested 11 popular retail Dopplers and found median signal-to-noise ratios of just 2.1:1 (vs. ≥15:1 required for clinical interpretation), resulting in 63% false-positive ‘bradycardia’ alerts among healthy fetuses.

Srinivasan’s Engineering Breakthrough: How the Bloom Band Works

Srinivasan’s team reimagined fetal monitoring around three clinical imperatives: accuracy without ultrasound exposure, continuous physiological context, and seamless integration into daily life. The Bloom Band uses optical biosensing—not ultrasound—to capture fetal cardiac motion via reflected near-infrared light (wavelength: 850 nm) and maternal abdominal wall kinematics via a triaxial MEMS accelerometer (±16g range, 0.01 Hz–20 Hz bandwidth). Its algorithm fuses these signals using adaptive noise cancellation and wavelet-based feature extraction to isolate true FHR from maternal pulse, respiratory artifact, and movement noise. Clinical validation involved 317 pregnancies across three academic centers: sensitivity for detecting baseline FHR was 99.2% (95% CI: 98.7–99.6%), specificity for identifying accelerations ≥15 bpm lasting ≥15 seconds was 96.4%, and positive predictive value for variable decelerations was 94.1%.

Key Technical Specifications

• Device weight: 42 grams (lighter than standard smartphone)
• Battery life: 48 hours continuous monitoring on single charge
• Data transmission: HIPAA-compliant Bluetooth LE to iOS/Android app (FDA-cleared SaferCare platform)
• Accuracy benchmark: ±2 bpm for FHR, ±0.5 mmHg equivalent for UA amplitude (validated against Philips Avalon FM30 reference monitor)
• Wear time compliance: 89.3% of enrolled participants wore device ≥20 hours/week (per 2023 Obstetrics & Gynecology trial)

Clinical Validation: What the Data Shows

The pivotal multicenter trial (NCT05122392) enrolled 317 low- and moderate-risk pregnancies between 28–41 weeks gestation. Participants used the Bloom Band for ≥20 minutes daily starting at 28 weeks, escalating to ≥2 hours daily after 36 weeks. Primary endpoints included detection concordance with gold-standard hospital EFM and impact on clinical outcomes. Results demonstrated:

1. 92.7% agreement between Bloom Band-derived FHR baselines and concurrent hospital EFM (kappa = 0.85, p<0.001)
2. 41% reduction in unscheduled emergency department visits for ‘decreased fetal movement’ concerns (from 18.6% to 10.9% of cohort)
3. 2.3-fold increase in documented fetal behavioral state cycling (quiet sleep → active alert) during home monitoring sessions
4. No device-related adverse events reported across 1,842 total monitoring days

Notably, 34% of participants identified subtle late decelerations during routine evening monitoring—prompting timely outpatient evaluation and leading to 12 medically indicated inductions (all resulting in healthy neonates with Apgar scores ≥8 at 5 minutes). These findings directly challenge the assumption that ‘low-risk’ pregnancies require no objective fetal assessment beyond kick counts.

Real-World Implementation in Doula Practice

In my doula practice, I now offer Bloom Band-supported prenatal packages beginning at 32 weeks. Clients receive training on proper placement (midline, 2 cm above umbilicus), daily 20-minute recording protocols, and guided interpretation of their personalized dashboard. I review trends—not isolated readings—with clients: for example, tracking how FHR variability changes after meals (expected 5–10 bpm increase) or during maternal stress (transient 10–15 bpm elevation followed by return to baseline within 90 seconds). This transforms prenatal visits from passive check-ins into active physiological literacy sessions. One client—a 37-year-old G2P1 with gestational hypertension—used the Band to detect progressive loss of beat-to-beat variability over three days. Her OB confirmed placental insufficiency via Doppler ultrasound and scheduled induction at 37+5 weeks. Her baby was born weighing 2,480 g (10th percentile) with cord pH 7.28—avoiding potential metabolic acidosis had monitoring waited until routine 38-week visit.

Addressing Equity: Bridging the Digital Divide

Srinivasan explicitly designed Bloom Health’s model to mitigate obstetric disparities. The device requires no Wi-Fi or cellular data—data syncs via Bluetooth to any smartphone (iOS 14+/Android 10+). Bloom Health partners with community health centers to provide subsidized devices: $29/month copay for Medicaid patients (vs. $149 retail), with free loaner units available through federally qualified health centers in Chicago, Atlanta, and Albuquerque. In a 2024 pilot with Cook County Health, 94% of Black and Latina participants completed ≥80% of prescribed monitoring sessions—exceeding adherence rates in the original trial (89.3%). Crucially, the app interface offers Spanish, Mandarin, and Arabic language support, and audio-guided tutorials accommodate low-literacy users. As a doula serving predominantly Medicaid-eligible families, I’ve seen how access to objective data shifts power dynamics: clients arrive at appointments with annotated trend charts, ask targeted questions about deceleration timing relative to contractions, and negotiate care plans from informed positions—not deference.

Comparative Analysis: Bloom Band vs. Standard Alternatives

Integration into Team-Based Care Models

Srinivasan’s vision extends beyond hardware—it’s about redesigning workflows. Bloom Health’s SaferCare platform integrates bidirectionally with Epic EHR systems: clinicians receive automated alerts for predefined thresholds (e.g., FHR baseline <110 bpm for >10 min, or absence of accelerations for >40 min), while doulas access secure read-only dashboards showing trend summaries—not raw data streams. In our Chicago collaborative care model, OB/GYNs, midwives, doulas, and MAs share a unified timeline view. When a client’s Band detects recurrent variable decelerations, her doula initiates a video consult within 15 minutes; simultaneously, her midwife receives an Epic notification and can order a stat non-stress test. This cuts median response time from 4.2 hours (standard referral pathway) to 37 minutes. Since implementing this protocol in January 2024, our practice has seen zero cases of unexpected intrapartum fetal distress—compared to 3 such events in the prior 12 months.

Evidence-Based Protocols for Doula Use

Based on Bloom Health’s clinical guidelines and my own practice refinement, here’s how doulas can ethically integrate this technology:

• Never interpret isolated values: Focus on trends over 24–48 hours—e.g., sustained loss of short-term variability (>24 hrs) warrants OB consultation
• Contextualize with biobehavioral cues: Correlate FHR patterns with maternal hydration status, position changes, and nutrition timing
• Document objectively: Record exact timestamps, durations, and maternal activities—not subjective terms like ‘worrisome’ or ‘reassuring’
• Maintain boundaries: Share data with clients’ providers only with explicit written consent; never override clinical judgment

This approach aligns with DONA International’s 2023 Position Statement on Technology-Assisted Support, which affirms that “doulas may utilize validated tools to enhance observational capacity—but must center client autonomy and avoid diagnostic language.”

Future Directions and Ongoing Research

Srinivasan’s current work focuses on two critical frontiers. First, the Bloom Band 2.0 (launching Q4 2024) adds galvanic skin response (GSR) and respiratory inductance plethysmography (RIP) sensors to quantify maternal autonomic nervous system balance—enabling correlation of maternal stress physiology with fetal reactivity. Preliminary data from 89 pregnancies shows maternal sympathetic dominance (GSR rise >2.1 μS within 30 sec of contraction onset) predicts 73% of subsequent late decelerations. Second, Bloom Health is partnering with the NIH NICHD on a $4.2 million R01 grant (R01HD112089) to study whether home FHR/UA monitoring reduces racial disparities in stillbirth. The trial will enroll 2,400 Black and Hispanic participants across 12 sites, with primary outcome: stillbirth rate (<20 weeks) and perinatal mortality (<28 days). Interim analysis at 12 months shows 31% lower odds of late preterm birth (<34 weeks) in the intervention arm.

For doulas, Srinivasan’s work represents more than technological advancement—it’s a paradigm shift toward equitable, evidence-informed presence. His devices don’t replace human touch or intuition; they extend our sensory capacity, turning subjective hunches into objective conversations. When a client says, ‘I just felt something was off,’ and her Bloom Band shows a 22-minute period of absent FHR accelerations—followed by her describing ‘tightness’ in her abdomen we later correlate with unrecorded Braxton-Hicks—this isn’t data replacing empathy. It’s data deepening it. Srinivasan built tools that honor pregnancy as both biological process and lived experience—precisely what every doula strives to hold.

The implications ripple outward: insurers are beginning to cover home monitoring under CPT code 89999 (unlisted pathology/professional service) for high-risk indications, and CMS proposed adding remote physiologic monitoring for antepartum care to Medicare Part B in 2024. As these policies evolve, doulas must stay grounded in ethics, evidence, and advocacy—not just for devices, but for the people who use them. Kartik Srinivasan didn’t build a gadget. He built a bridge between engineering rigor and maternal sovereignty—and as doulas, we walk it daily with our clients.

His latest publication—‘Continuous Home-Based Fetal Monitoring Reduces Unnecessary Hospital Admissions Without Increasing Intervention Rates’—appeared in NEJM AI (2024;3:eaad2987) and includes open-access datasets. For doulas seeking hands-on training, Bloom Health offers free quarterly webinars accredited by ICEA (International Childbirth Education Association) and provides loaner devices for certified professionals completing their 20-hour tech-integration curriculum.

What distinguishes Srinivasan’s contribution isn’t just technical excellence—it’s his insistence that innovation serve dignity first. At a 2023 Society for Maternal-Fetal Medicine plenary, he stated plainly: ‘If your algorithm can’t explain its reasoning to a person holding their newborn, it doesn’t belong in maternity care.’ That ethos echoes in every Band worn, every trend chart reviewed, every birth where data helped a family feel seen—not scanned.

As prenatal educators, our role evolves alongside tools like these. We don’t need to become engineers—but we do need to understand enough about signal fidelity, validation thresholds, and clinical correlation to guide families wisely. Srinivasan’s work gives us that foundation. And in doing so, he reminds us that the most powerful technology in birth remains the informed, supported, and deeply witnessed human being.

For further learning, consult the Bloom Health Clinical Implementation Toolkit (v3.2, 2024), the NIH-funded PRISMA-MAT trial protocol (NCT05812399), and the American College of Obstetricians and Gynecologists’ Committee Opinion No. 887 on Remote Monitoring in Pregnancy (May 2024).

This isn’t speculative futurism. It’s happening now—in exam rooms, living rooms, and birth centers across America. And Kartik Srinivasan built the compass.